{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"44"},{"groupId":"OG003","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"77"},{"groupId":"OG002","value":"49"},{"groupId":"OG003","value":"50"}],"units":"Participants"}],"description":"The response rate was defined as the number (proportion) of patients with the last 72-hour nadir serum asparaginase activity (NSAA) level ≥ 0.1 IU/mL during the first course of IM JZP-458. Blood samples were collected for serum asparaginase activity level determination.","groups":[{"description":"Participants who received an intramuscular (IM) dose of JZP-458 25 mg/m\\^2 on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks based on available data from the Phase 1 (JZP458-101) healthy volunteer study.","id":"OG000","title":"Part A: JZP-458 IM 25 mg/m^2 (MWF)"},{"description":"Participants who received an intramuscular (IM) dose of JZP-458 37.5 mg/m\\^2 on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG001","title":"Part A: JZP-458 IM 37.5 mg/m^2 (MWF)"},{"description":"Participants who received an intramuscular (IM) dose of JZP-458 25 mg/m\\^2 on Mondays and Wednesdays and 50 mg/m\\^2 on Fridays on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG002","title":"Part A: JZP-458 IM 25 (MW)/50 mg/m^2 (F)"},{"description":"Participants who received an intravenous (IV) dose of JZP-458 25 mg/m\\^2 on Mondays and Wednesdays and 50 mg/m\\^2 on Fridays on a Monday/Wednesday/Friday (MWF) schedule over 2 weeks.","id":"OG003","title":"Part B: JZP-458 IV 25 (MW)/50 mg/m^2 (F)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Response rates were assessed in the Efficacy Analysis Set in participants with available data.","reportingStatus":"POSTED","timeFrame":"Baseline up to 2 weeks","title":"Response Rate During the First Course of JZP-458 Administration","type":"PRIMARY","unitOfMeasure":"Participants"}